Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Myriberine A in preparation of a medicine for treating rhinitis

A technology for medicine and rhinitis, which is applied in the application field of Myriberine A in the preparation of medicine for treating rhinitis, and can solve the problems of ineffectiveness and poor curative effect of rhinitis.

Inactive Publication Date: 2013-10-02
张关池
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used in the treatment of rhinitis. These drugs have poor or ineffective effects on chronicity and recurrent rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myriberine A in preparation of a medicine for treating rhinitis
  • Application of Myriberine A in preparation of a medicine for treating rhinitis
  • Application of Myriberine A in preparation of a medicine for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1: Preparation of the compound Myriberine A tablet of the present invention:

[0014] Take 5 grams of compound Myriberine A, add 195 grams of dextrin, mix well, and routinely press into 1000 tablets.

Embodiment 2

[0015] Example 2: Preparation of the compound Myriberine A capsules involved in the present invention:

[0016] Take 5 grams of compound Myriberine A, add 195 grams of starch, mix well, and put into capsules to make 1000 capsules.

[0017] The pharmacodynamics experiment will further illustrate its drug activity below.

experiment example 1

[0018] Experimental Example 1. The effect of Myriberine A of the present invention on ovalbumin-induced allergic rhinitis in rats

[0019] Male SD rats, experimental animal center of Nanjing Medical University, weighing 180-220 g, were injected intraperitoneally with 1 mg of ovalbumin and 10 mg of aluminum hydroxide gel, and then once every other day, for a total of 7 times. From the 14th day, 10ul of 1 mg / ml ovalbumin physiological saline solution was instilled into the nasal cavity of the rats on both sides of the rats every day, a total of 7 times. The times of sneezing and wiping the nose of the rats within 30 minutes were observed immediately after the last infusion, and the test drug was orally administered 1 hour before the last infusion of ovalbumin.

[0020] Table 1 The effect of Myriberine A of the present invention on ovalbumin-induced allergic rhinitis in rats (x±SD)

[0021]

[0022] Compared with the control group, **P<0.01*P<0.05

[0023] It can be seen fro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses Myriberine A which is used for treating immunity inflammation, used for preparing a medicine for treating the immunity inflammation, and particularly suitable for preparing a medicine for treating rhinitis, and terfenadine and diclofenac sodium are used as comparison, the curative effect of Myriberine A is clear. An application of Myriberine A in preparation of the medicine for treating rhinitis is firstly disclosed, due to the fact that a skeleton type is brand new, activity for treating rhinitis is strong unexpectedly, the possibility of any inspiration provided by other compounds does not exist, Myriberine A has outstanding substantive feature and obvious improvement for preventing and curing rhinitis.

Description

technical field [0001] The invention relates to a new use of the compound Myriberine A, in particular to the application of Myriberine A in the preparation of a medicament for treating rhinitis. Background technique [0002] Rhinitis is a common clinical disease and frequently-occurring disease. The occurrence of rhinitis is mainly related to allergic reactions and belongs to the category of immune inflammation. At present, antihistamines such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used for the treatment of rhinitis. Therefore, small molecule compounds with clear composition, controllable quality, safety and high efficiency have potential value in the development of rhinitis treatment drugs. [0003] The compound Myriberine A involved in the present invention was published in 2013 (Sheng-Dian Huang, et al., Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi. Organic Letters, 2012, 3(...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P11/02A61P37/08
Inventor 张关池
Owner 张关池
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com